Breaking Down Haisco Pharmaceutical Group Co., Ltd. Financial Health: Key Insights for Investors

Founded in 2000 and listed on the Shenzhen Stock Exchange (SZSE: 002653), Haisco Pharmaceutical Group has grown into a diversified, innovation-led drug developer whose portfolio spans more than 70 varieties-many first or exclusive generics in China-and addresses critical areas like liver disease, parenteral nutrition, depression and antibiotics; backed by an in-house R&D force of over 800 scientists that have brought 45 new products to market, Haisco couples a patient-centric mission-"cherish every life, share constantly and promptly, focus on the recovery of patients with innovative and pragmatic attitude of development"-with a global ambition to "become the most trusted international pharmaceutical enterprise," supported by distribution into more than 10,000 Grade II+ hospitals across China, a sales team of 1,000+ personnel and nearly 5,000 management representatives, plus R&D presence overseas via Haisco‑USA Pharmaceuticals, Inc., all grounded in core values of innovation, integrity, pragmatism and efficiency that drive its strategy and operations.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) - Intro

• Founded: 2000
• Stock code: 002653.SZ (Shenzhen Stock Exchange)
• Therapeutic coverage: liver disease, parenteral nutrition, depression, antibiotics, and others
• Product portfolio: >70 varieties, many first- or exclusive-generics in China
• New products listed: 45

• Advance patient care through innovative, affordable, and high-quality pharmaceuticals.
• Deliver reliable hospital and community healthcare solutions across China and selected global markets.
• Maintain rigorous quality and compliance standards throughout development and manufacturing.

• Be a leading Chinese-origin pharmaceutical innovator with a global footprint in specialty and complex generics.
• Create sustainable long-term value for patients, healthcare partners, employees, and shareholders by combining R&D excellence with scalable production and distribution.

• Innovation - sustained investment in R&D (800+ research staff; 45 listed new products).
• Quality & Compliance - GMP-aligned manufacturing and regulatory focus for first/exclusive generics.
• Patient-first - product portfolios targeting underserved therapeutic areas such as liver disease and parenteral nutrition.
• Collaboration - integrated sales network covering 10,000+ hospitals and a field force supporting market access.
• Global-mindedness - strategic presence in U.S./EU drug development through Haisco-USA.

• Pipeline acceleration: leveraging in-house R&D to expand beyond 45 listed new products into higher-value specialty medicines.
• Manufacturing scale: supporting a diversified product mix including sterile injectables and oral dosage forms for hospital-centric markets.
• Commercial reach: optimizing a sales network of >1,000 reps and ~5,000 management representatives to sustain hospital penetration and product adoption.
• International expansion: advancing regulatory strategy and clinical development via Haisco-USA for U.S./EU market entry.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ): Overview

• Haisco's mission is to 'cherish every life, share constantly and promptly, focus on the recovery of patients with innovative and pragmatic attitude of development.'
• This mission underscores a patient-centric strategy prioritizing recovery, access, and timely delivery of therapies.
• It frames the company's dual emphasis on innovation and practical, scalable solutions for clinical needs.
• The stated mission has been consistently maintained in Haisco's corporate communications, guiding R&D choices, manufacturing investments, and market expansion.

• To be a leading global pharmaceutical enterprise recognized for reliable, clinically effective medicines and continuous innovation across therapeutic areas.
• To expand international reach while maintaining high-quality manufacturing, regulatory compliance, and sustainable growth.

• Patient-first: prioritizing treatments and services that improve patient outcomes.
• Innovation with pragmatism: advancing novel therapies and formulations while ensuring manufacturability and affordability.
• Quality and compliance: adherence to strict quality control, GMP standards, and regulatory requirements.
• Responsibility to society: improving public health through access, education, and corporate citizenship.
• Collaboration: fostering internal and external partnerships with hospitals, research institutes, and international partners.

• R&D prioritization: pipeline and new formulations chosen for clinical impact and scalability to serve more patients promptly.
• Manufacturing investment: capacity and compliance investments align with quality-first value to ensure stable supply to hospitals and distributors.
• Market strategy: focus on hospital channel and specialty segments where patient recovery outcomes and product reliability matter most.

• Targeted development of therapies addressing high-burden conditions in hospital settings to improve recovery rates and reduce length of stay.
• Process improvements to speed time-to-patient while controlling cost - reflecting 'share constantly and promptly.'
• Partnerships with clinical centers to gather real-world data and iterate on product value in practice.

• Consistent mission and values provide a stable framework for long-term planning, risk management, and capital allocation.
• Operational transparency and quality focus reduce regulatory and supply-chain risks valued by institutional investors.
• For more investor-oriented detail: Exploring Haisco Pharmaceutical Group Co., Ltd. Investor Profile: Who's Buying and Why?

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) - Mission Statement

• Patient-centered product development: prioritize therapies with clear clinical value and favorable benefit-risk profiles.
• Quality and compliance: maintain GMP-standard manufacturing, robust QC systems and transparent regulatory reporting.
• Globalization: expand international registration, licensing and distribution to serve broader patient populations.
• Stakeholder trust: uphold ethical business practices, supplier governance and long-term partnerships with healthcare providers and regulators.
• Sustainable growth: balance commercial expansion with reinvestment in R&D and environmental responsibility.

Vision Statement: 'To become the most trusted international pharmaceutical enterprise'

• Internationalization - progressive increase in overseas registrations and export footprint.
• Trust - emphasis on pharmacovigilance, quality management and transparent reporting.
• Ethical governance - corporate compliance and adherence to global standards.
• Long-term stakeholder relationships - distribution partners, clinicians and patients.

• Operational focus areas tied to the vision:
  • Scaling international regulatory capabilities to accelerate foreign approvals.
  • Strengthening pharmacovigilance and post-marketing surveillance to reinforce trust.
  • Investing in digital quality systems and supply‑chain traceability to ensure product integrity.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) - Vision Statement

• Innovation - continuous investment in R&D to expand therapeutic offerings and introduce first/exclusive generics.
• Integrity - strict compliance with regulatory requirements, quality standards, and ethical practices across the value chain.
• Pragmatism - market-driven, practical deployment of assets and diversified marketing models to capture demand effectively.
• Efficiency - operational excellence and productivity improvements to meet market needs while controlling costs.

• R&D focus: sustained pipeline growth, enabling the company to offer over 70 drug varieties, including numerous first or exclusive generics in China.
• Regulatory compliance: quality systems and audit-readiness embedded across manufacturing sites and distribution to uphold integrity.
• Marketing and distribution: diversified channels (direct sales, distributors, hospital partnerships) to pragmatically maximize reach.
• Manufacturing efficiency: process optimization and capacity planning to ensure timely supply and margin stability.

• Innovation → product pipeline expansion and market differentiation via exclusive generics and new formulations.
• Integrity → lower regulatory risk, stronger hospital and insurer relationships, and enhanced stakeholder trust.
• Pragmatism → flexible commercialization strategies that translate clinical assets into market share efficiently.
• Efficiency → improved production yields, tighter inventory turns, and better margin control supporting reinvestment.